A delayed U.S. Drug Enforcement Administration ban on kratom would stifle scientific understanding of the herb’s active chemical components and documented pharmacologic properties if implemented, according to a special report published in The Journal of the American Osteopathic Association.
The report cited the pharmacologically active compounds in kratom, including
- speciogynine and
- 20 other substances,
as one basis for further study.
View original post 262 more words